A method for treating or reducing the risk of a ryanodine receptor (RyR) associated condition, disorder, or disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound having the formula: wherein: R1, R1, R2, R2, R3, and R3 independently are selected from H and an electron-donating group, or alternatively, when R3 and R3 are bonded to two adjacent carbon atoms, R3 and R3, together with the two adjacent carbon atoms, form a 5-membered monocyclic moiety which is fused to the phenyl group and comprises 1-2 heteroatoms selected from O, S, and N provided that: when each of R1, R2, R2, R3 and R3 is H, R1 is not -OCH3 when R1 is -OCH3, at least one of R1, R2, R2, R3 and R3 is not H when R1 is -OCH3 and R3 and R3 are both NH2, at least one of R1, R2, and R^ is not H when R1 is -OCH3 and R3 and R3 are H and NH2, at least one of R1, R2, R2, R3 and R3 is not H and when R1 is OH, at least one of R1, R2, R2, R3 and R3 is not H or a pharmaceutically acceptable salt, hydrate, ester, or prodrug thereof.